Supplementary Materials

The PDF file includes:

  • Materials and Methods
  • Fig. S1. Ipilimumab, nivolumab, and pembrolizumab responders and nonresponders with low melanoma neoantigen loads.
  • Fig. S2. Characterization of UV2 and UV3 melanoma cell lines.
  • Fig. S3. RNA sequencing reveals enhanced cytotoxic activity and upregulation of T cell dysfunction markers in UV2 melanomas compared to parental D4M.3A.3 melanomas.
  • Fig. S4. Addition of imiquimod and aFP to immune checkpoint blockade induces an abscopal effect in mice bearing melanomas or pancreatic ductal adenocarcinomas.
  • Fig. S5. Combination immunotherapy improves T cell responses and is associated with markers of increased DC infiltration and function.
  • Fig. S6. Melanoma treatment with combination immunotherapy promotes melanocyte antigen expression and immune elimination of melanomas, but not pancreatic tumors.
  • References (3744)

[Download PDF]

Other Supplementary Material for this manuscript includes the following: